Protozoal Infections

Entamoeba histolytica — Amoebiasis

A faecal–oral amoeba that exists in two forms: an inactive cyst that survives outside the body and spreads infection, and a mobile trophozoite that does the damage. Most infections stay in the colon and cause amoebic dysentery — bloody diarrhoea, cramping, tenesmus. In a minority the trophozoites breach the gut wall and travel by portal blood to the liver, producing an amoebic liver abscess; spread to lung, brain or spleen is rarer still.

Roughly 50 million symptomatic cases a year. Treatment is metronidazole or tinidazole for the invasive infection plus a luminal agent such as paromomycin to clear the cysts — a two-drug logic that catches people out, because clearing the symptoms does not clear the carriage.

Giardia duodenalis — Giardiasis

The most common intestinal protozoan in most of the world, with something like 280 million symptomatic cases a year. It attaches to the lining of the small intestine with a ventral sucking disc rather than invading, and the damage is functional rather than destructive: villous blunting, brush-border enzyme loss, malabsorption. The result is watery, greasy, foul-smelling diarrhoea, bloating, sulphurous belching and weight loss.

Transmission is faecal–oral, classically through untreated surface water — the reason it is the archetypal hiker’s and traveller’s infection. Metronidazole, tinidazole or nitazoxanide clear it. Post-giardial lactose intolerance and post-infectious IBS are common and can outlast the parasite by months, and that is where a supportive role exists.

Cryptosporidium

An oocyst-forming coccidian, and one of the leading causes of moderate-to-severe diarrhoea in children under two in low-income settings. Its oocysts are chlorine-resistant, which is why it causes swimming-pool and municipal-water outbreaks in wealthy countries too. In the immunocompetent it is self-limiting; in advanced HIV it can cause intractable, wasting diarrhoea. Nitazoxanide is the only approved drug and works poorly in exactly the patients who most need it — a real gap in conventional care, and one no botanical has come close to filling.

Cyclospora & Blastocystis

Cyclospora cayetanensis causes foodborne outbreaks traced to fresh produce; it responds to co-trimoxazole and notably not to metronidazole. Blastocystis is among the most common organisms found in human stool and its pathogenicity is disputed — it is frequently present in people with no symptoms at all, and treating it is often unnecessary.

Trichomonas vaginalis

The most common non-viral sexually transmitted infection, with something like 156 million new infections a year. Frothy discharge, irritation and dysuria in women; usually asymptomatic in men, who nonetheless transmit it. Metronidazole or tinidazole, treating partners simultaneously.

Leishmania

Transmitted by sandflies, and it presents as three quite different diseases depending on species and host immunity:

• Cutaneous leishmaniasis (CL) — chronic skin ulcers at the bite site. 600,000 to a million new cases a year. Disfiguring, but frequently self-healing over months, which inflates cure rates in treatment trials.
• Mucocutaneous — destructive spread to the nose and mouth, mainly in the Americas.
• Visceral leishmaniasis (VL, kala-azar) — the parasite disseminates to spleen, liver and bone marrow. 50,000 to 90,000 new cases a year, and over 95% fatal untreated.

Treatment ranges from cryotherapy and topical paromomycin for simple skin lesions to liposomal amphotericin B, miltefosine or pentavalent antimonials for visceral disease.

Trypanosoma

Two organisms, two continents, two diseases. T. cruzi causes Chagas disease, transmitted by triatomine “kissing bugs” in the Americas — 6 to 7 million people infected. The acute phase is often silent; decades later, chronic infection produces cardiomyopathy, conduction disease, and megaoesophagus or megacolon. Benznidazole and nifurtimox clear the parasite but do not reverse established organ damage.

T. brucei causes African sleeping sickness, transmitted by tsetse flies. Stage one is fever, joint pain and lymphadenopathy; stage two is invasion of the central nervous system, with the reversed sleep–wake cycle, personality change and eventual coma that name the disease. It has been driven close to elimination — fewer than a thousand reported cases a year — and oral fexinidazole has transformed treatment.

Toxoplasma gondii

Around a third of the world’s population carries Toxoplasma as latent tissue cysts, acquired from undercooked meat or cat faeces. In healthy people it is almost always silent. It matters in two situations: primary infection during pregnancy, which can cause chorioretinitis, hydrocephalus and intracranial calcification in the fetus; and reactivation in immunosuppression, classically toxoplasmic encephalitis in advanced HIV. Pyrimethamine plus sulfadiazine with leucovorin. No drug reliably clears the latent cysts, and that remains the unsolved problem in this organism.

Babesia

Tick-borne, intraerythrocytic, and clinically a malaria mimic — fever, haemolytic anaemia, and severe disease in people without a spleen or with compromised immunity. Rising in the north-eastern United States and often co-transmitted with Lyme disease by the same Ixodes tick. Atovaquone plus azithromycin, or clindamycin plus quinine.

Free-Living Amoebae

Naegleria fowleri — the “brain-eating amoeba” — lives in warm fresh water, enters via the nose, and causes primary amoebic meningoencephalitis. It is rare and over 97% fatal. Acanthamoeba causes a sight-threatening corneal infection strongly associated with contact-lens wear and tap-water rinsing, and rarely a granulomatous brain infection.

The volume of botanical literature runs opposite to the human evidence. The parasites with the most botanical papers in this group — Leishmania promastigotes, Trypanosoma cruzi epimastigotes, Acanthamoeba — are the ones that grow cheaply in microplates. A PubMed search for T. cruzi plus plant extract returns over 400 records; Acanthamoeba nearly 100. Human-trial searches for giardiasis or amoebiasis botanicals return single digits.

The only botanicals with any human trial data in this group target Giardia, colonic amoebiasis, and cutaneous leishmaniasis. Visceral leishmaniasis, Chagas, Toxoplasma, Cryptosporidium, Cyclospora, Blastocystis, Babesia, Trichomonas and the free-living amoebae have zero verifiable human botanical trials — everything is in vitro or animal.

Visceral leishmaniasis (>95% fatal untreated), Naegleria meningoencephalitis (~97% fatal) and systemic Chagas have no human botanical data, and no plant is a treatment option for any of them. These are in vitro lead territory, nothing more.

Giardiasis — The Densest Human Signal

Berberine — the isoquinoline alkaloid of barberry, goldenseal and Coptis — has a small human record against Giardia. Two small paediatric trials in the 1970s reported that oral berberine (roughly 5–10 mg/kg/day) cleared or reduced Giardia in children ^{1Reference 1Choudhry et al. · 1972Berberine in giardiasis2Reference 2Gupte · 1975Use of berberine in treatment of giardiasis}. Both are old, neither has an abstract, and neither gives a verifiable cure rate: reported as effective, but not quantifiable. No modern trial has replicated them. In vitro, berberine sulphate inhibits Entamoeba, Giardia and Trichomonas, with chromatin clumping and autophagic vacuoles visible on electron microscopy ^{3Reference 3Kaneda et al. · 1991In vitroIn vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis4Reference 4Kaneda et al. · 1990Effects of berberine, a plant alkaloid, on the growth of anaerobic protozoa in axenic culture}.

Berberine’s oral bioavailability is under 1%. Systemic levels never approach the concentrations that inhibit these organisms in a dish. Any real effect must therefore be a luminal one — berberine acting on contact in the gut. That is entirely consistent with an effect on intestinal Giardia and Entamoeba, and it is a reason to expect nothing at all against systemic protozoa. Contraindicated in neonates (bilirubin displacement) and pregnancy; inhibits CYP3A4, P-gp and UGT1A1.

Garlic has one small open study in 26 children with G. lamblia, reporting crude garlic extract to be effective, safe and to shorten treatment — uncontrolled, with no cure percentage and no comparison against metronidazole ^{5Reference 5Soffar et al. · 1991Evaluation of the antiparasitic effect of aqueous garlic (Allium sativum) extract in hymenolepiasis nana and giardiasis}. The mechanistic work is better than the clinical work: allicin strongly inhibits Entamoeba cysteine proteinases and blocks its cytopathic effect on cell monolayers ^{6Reference 6Ankri et al. · 1997Allicin from garlic strongly inhibits cysteine proteinases and cytopathic effects of Entamoeba histolytica}, and diallyl trisulfide has IC50s of 14 µg/mL against Giardia and 59 µg/mL against Entamoeba ^{7Reference 7Lun et al. · 1994In vitroAntiparasitic activity of diallyl trisulfide (Dasuansu) on human and animal pathogenic protozoa in vitro}. Whether luminal concentrations reach those figures is unquantified.

Propolis was compared with tinidazole in a 1988 trial of 138 patients, which found parasitological cure in 52% of children at 10% concentration and 60% of adults at 30%, against 40% for tinidazole ^{8Reference 8Miyares et al. · 1988Clinical trialClinical trial with a preparation based on propolis “propolisina” in human giardiasis}. Non-blinded, and nearly forty years old. Propolis is not one substance: its composition varies enormously with geography and the plants the bees worked, so a dose from one study does not transfer to another product. Contact allergy is common.

Amoebiasis

Glaucarubin, a quassinoid glycoside isolated from simarouba bark, was used to treat human colonic amoebiasis in a 1956 series ^{9Reference 9VAN ASSENDELFT et al. · 1956Glaucarubin in the treatment of colonic amebiasis}. The data are human but archival: superseded by metronidazole, with no modern replication and a therapeutic index that was never properly characterised. Quassinoids are emetic and GI-toxic at higher doses.

In pomegranate, the plant part decides the activity. Aqueous root extract inhibited E. histolytica almost completely in vitro — while the isolated alkaloid from that same root was not amoebicidal, leaving the active principle unidentified ^{10Reference 10Segura et al. · 1990Growth inhibition of Entamoeba histolytica and E. invadens produced by pomegranate root}. Separately, peel polyphenols damaged Giardia trophozoite cytoskeleton ^{11Reference 11Palomo-Ligas L et al. · 2022In vitroAnti-Giardia activity of Punica granatum peel polyphenolic extract — in vitro and in silico}. Root bark, peel and juice are three different materials, and the root bark carries pelletierine alkaloids with a real historical toxicity record — vomiting, vertigo, mydriasis, collapse.

Cutaneous Leishmaniasis — Where The Randomised Trials Are

A skin lesion can be treated topically, so achievable local concentration is not the barrier it is systemically.

Juniper (Juniperus excelsa): in a triple-blind randomised placebo-controlled trial of 72 patients, topical juniper cream added to cryotherapy gave 82% complete cure against 34% for cryotherapy plus placebo ^{12Reference 12Parvizi MM et al. · 2017RCTTopical Juniperus excelsa cream as adjuvant to cryotherapy in Old World cutaneous leishmaniasis: a triple-blind randomised placebo-controlled trial}. Adjuvant, not monotherapy, single-centre, and needing replication.

A cluster of Iranian trials of multi-herb topical ointments points the same way. A combined herbal product added to intralesional Glucantime gave 82.4% complete healing at four weeks against 20.6% for placebo plus Glucantime in a double-blind RCT of 68 patients ^{13Reference 13Bozorgzade SA et al. · 2024RCTCombined herbal product as adjuvant to intralesional Glucantime in cutaneous leishmaniasis: a double-blind randomised trial}. A Shirvan herbal ointment reduced mean lesion size to zero against 11.1 mm for the control, with a shorter treatment course ^{14Reference 14Aghaei M et al. · 2024Shirvan herbal ointment versus Glucantime for cutaneous leishmaniasis: a controlled trial}, and two earlier double-blind trials of a topical extract called Z-HE compared it with systemic meglumine antimoniate ^{15Reference 15Zerehsaz F et al. · 1999RCTTopical herbal extract “Z-HE” versus meglumine antimoniate in cutaneous leishmaniasis: a double-blind randomised clinical trial16Reference 16Momeni AZ · 2000RCTZ-HE topical treatment of cutaneous leishmaniasis — companion double-blind randomised trial} — though those two have no extractable numbers in their indexed metadata.

Cutaneous leishmaniasis frequently self-heals. Spontaneous resolution inflates cure rates in single-arm and short-follow-up studies, and even the placebo-controlled results need multicentre replication. The formulations are also mostly proprietary and undisclosed, so none is reproducible from the papers alone, and none of it transfers to visceral disease.

In BALB/c mice, topical thyme, yarrow and propolis extracts outperformed systemic Glucantime for ulcer size — but Glucantime worsened ulcers in that model (−22.6%), which suggests a model artefact rather than a botanical triumph ^{17Reference 17Nilforoushzadeh MA et al. · 2008AnimalComparison of topical thyme, yarrow and propolis extracts with systemic glucantime in murine cutaneous leishmaniasis}.

Artemisinin — A Large Literature, No Human Trials

Artemisinin and Artemisia annua have the largest non-malaria antiprotozoal literature in this entire group and zero human trials against any of it.

Leishmania plus artemisinin returns 76 PubMed records; Toxoplasma plus artemisinin returns 58; there is a substantial Chagas body on top. Artemisinin kills Leishmania promastigotes and amastigotes, T. cruzi epimastigotes and Toxoplasma in vitro and ex vivo, with a plausible mechanism — iron- and haem-activated radical generation, apoptosis-like death, and in Toxoplasma an effect on calcium handling mapped through resistant mutants ^{18Reference 18Loo et al. · 2017Artemisinin and its derivatives in treating protozoan infections beyond malaria19Reference 19Solano-Gálvez et al. · 2024In vitroArtemisinin targets Leishmania and activates apoptosis of infected host cells — in vitro20Reference 20Cortes S et al. · 2015In vitroSusceptibility of Leishmania infantum to artemisinin trioxanes and synthetic trioxolanes — in vitro21Reference 21Berrizbeitia de Morgado et al. · 2016In vitroArtemisia annua infusion against Trypanosoma cruzi epimastigotes — in vitro22Reference 22Nagamune et al. · 2007Artemisinin-resistant Toxoplasma gondii mutants show altered calcium homeostasis}.

Every one of those records is in vitro or animal. The “human” hits returned by artemisinin plus clinical-trial searches are malaria trials or case reports, not trials against these organisms. Much of the Chagas work uses epimastigotes — the insect stage — which is a weak predictor of activity against the intracellular amastigote that actually causes disease in people. Many of the reported IC50s exceed the plasma levels reached with antimalarial dosing, and artemisinins have very short half-lives.

Artemisinin’s real human indication is malaria, and it is a triumph there. Its reputation against these other protozoa is entirely preclinical.

Toxoplasmosis & The Rest

Nigella sativa seed oil reduced parasite burden in experimental murine toxoplasmosis, including a chronic-infection model ^{23Reference 23Mady RF et al. · 2015AnimalEffect of Nigella sativa oil on experimental murine toxoplasmosis24Reference 24Mohammad OS et al. · 2023AnimalNigella sativa oil-loaded metal-organic framework in chronic murine toxoplasmosis}, and shows activity against L. major stages in vitro ^{25Reference 25Rokni N et al. · 2021In vitroPeganum harmala and Nigella sativa against Leishmania major — in vitro and ex vivo}. Animal only. Latent-cyst clearance is the unsolved problem in Toxoplasma, and animal signals in cyst clearance have a poor record of translating to people.

Turmeric appears in the leishmaniasis literature. The most active molecule in that work — dibenzalacetone — is a synthetic analogue, not a turmeric constituent ^{26Reference 26Chauhan et al. · 2018Dibenzalacetone induces apoptosis-like death in Leishmania donovani amastigotes}. And curcumin’s oral bioavailability is poor enough that the in vitro concentrations are not reachable. No human antileishmanial data exists ^{27Reference 27Albalawi AE et al. · 2021Systematic reviewAntileishmanial effects of curcumin: a systematic review}.

For Cryptosporidium, Cyclospora, Blastocystis, Babesia and the free-living amoebae there is no verified botanical human evidence of any kind. In vitro screens exist for several; none has advanced. Given that nitazoxanide itself performs poorly in immunocompromised cryptosporidiosis, that gap is real and unfilled.